Is MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Halal?

NASDAQ Healthcare United States $1.1B
✗ NOT HALAL
Confidence: 90/100
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) is Not Halal under AAOIFI Standard 21. The company's impermissible income ratio of 6.16% exceeds the 5% threshold allowed under AAOIFI. MARAVAI LIFESCIENCES HOLDINGS, INC. operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 27.9%
/ 30%
16.6%
/ 30%
2.0%
/ 30%
6.16%
/ 5%
✗ NOT HALAL
DJIM 27.9%
/ 33%
16.6%
/ 33%
2.0%
/ 33%
6.16%
/ 5%
✗ NOT HALAL
MSCI 47.3%
/ 33%
28.1%
/ 33%
3.3%
/ 33%
6.16%
/ 5%
✗ NOT HALAL
S&P 27.9%
/ 33%
16.6%
/ 33%
2.0%
/ 33%
6.16%
/ 5%
✗ NOT HALAL
FTSE 47.3%
/ 33%
28.1%
/ 33%
3.3%
/ 50%
6.16%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-0.90
P/B Ratio
2.0
EV/EBITDA
-9.8
EV: $727M
Revenue
$186M
Growth: -11.8%
Beta
0.3
Low volatility
Current Ratio
6.6

Profitability

Gross Margin 19.2%
Operating Margin -39.4%
Net Margin -70.4%
Return on Equity (ROE) -48.6%
Return on Assets (ROA) -8.8%

Cash Flow & Balance Sheet

Operating Cash Flow-$58M
Free Cash Flow-$71M
Total Debt$365M
Debt-to-Equity97.9
Current Ratio6.6
Total Assets$771M

Price & Trading

Last Close$3.09
50-Day MA$3.33
200-Day MA$3.04
Avg Volume1.3M
Beta0.3
52-Week Range
$1.67
$4.11

About MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)

CEO
Mr. Bernd Brust
Employees
435
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$1.1B
Currency
USD

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), MARAVAI LIFESCIENCES HOLDINGS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is MARAVAI LIFESCIENCES HOLDINGS, INC.'s debt ratio?

MARAVAI LIFESCIENCES HOLDINGS, INC.'s debt ratio is 27.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 47.3%.

What are MARAVAI LIFESCIENCES HOLDINGS, INC.'s key financial metrics?

MARAVAI LIFESCIENCES HOLDINGS, INC. has a market capitalization of $1.1B, and revenue of $186M. The company maintains a gross margin of 19.2% and a net margin of -70.4%. Return on equity stands at -48.6%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.